How many insider trades does FilingIQ track for CTNM?

FilingIQ tracks 53 Form 4 insider transactions for CTNM (Contineum Therapeutics, Inc.), covering filings from Apr 9, 2024 onwards. 22 of those were filed in the last 90 days.

Are CTNM insiders net buyers or net sellers?

Across the full Form 4 history for CTNM, 0 transactions (0%) were open-market purchases and 23 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CTNM insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CTNM in?

Contineum Therapeutics, Inc. (CTNM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $522.37M.

CTNM insider trading

Healthcare

Contineum Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 43%

Market cap

$522.37M

About Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Company website: www.contineum-tx.com

CTNM insider activity at a glance

FilingIQ has scored 53 insider transactions for CTNM since Apr 9, 2024. The most recent filing in our index is dated May 1, 2026.

Across the full history, 0 open-market purchases and 23 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CTNM insider trades is 51.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CTNM trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding CTNM

JOHNSON & JOHNSON (JNJ)

$23.26M · 4.6% of AUM

Casdin Capital, LLC

$5.22M · 0.4% of AUM

Frequently asked

How many insider trades does FilingIQ track for CTNM?: FilingIQ tracks 53 Form 4 insider transactions for CTNM (Contineum Therapeutics, Inc.), covering filings from Apr 9, 2024 onwards. 22 of those were filed in the last 90 days.
Are CTNM insiders net buyers or net sellers?: Across the full Form 4 history for CTNM, 0 transactions (0%) were open-market purchases and 23 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CTNM insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CTNM in?: Contineum Therapeutics, Inc. (CTNM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $522.37M.

Methodology & sources

Every CTNM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.